Every eligible trial reported a tolerable safety profile, and the most frequent AEs were fatigue, rash, nausea, increasing alanine aminotransferase, anemia, diarrhea, and increasing aspartate aminotransferase, with incidences of 0.272, 0.180, 0.157, 0.143, 0.135, 0.127, and 0.102, respectively. This evidence concerns the gene GPT and anemia (phenotype).